Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | MAOB | P27338 | 2/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
| ▸ | ACACB | O00763 | 1/20 | 0.46 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | SRD5A1 | P18405 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | CASP1 | P29466 | 1/20 | 0.46 |
| ▸ | CASP7 | P55210 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | DRD5 | P21918 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3307342 | 0.95 | DRD1 (0.51) | MAOAMAOBSLC6A4ALDH1A1KDM4E | |
| SCHEMBL12608358 | 0.94 | HDAC6 (0.50) | ALDH1A1KDM4EGAAACACBSRD5A1 | |
| SCHEMBL29715895 | 0.89 | NAMPT (0.50) | ALDH1A1KDM4EGAAACACBLMNA | |
| SCHEMBL3308449 | 0.89 | NAMPT (0.50) | ALDH1A1KDM4EGAAACACBLMNA | |
| SCHEMBL13181779 | 0.85 | ACACB (0.47) | ALDH1A1KDM4EACACBLIPESRD5A1 | |
| SCHEMBL27949705 | 0.85 | ACACB (0.45) | ALDH1A1KDM4EACACBLIPESRD5A1 | |
| SCHEMBL30810841 | 0.84 | HDAC6 (0.51) | KDM4EACACBLMNA | |
| SCHEMBL17560214 | 0.84 | NOTUM (0.56) | KDM4EACACB | |
| SCHEMBL2277266 | 0.84 | HDAC6 (0.51) | KDM4EACACBLMNA | |
| SCHEMBL14305560 | 0.84 | ALDH1A1 (0.58) | ALDH1A1KDM4ESRD5A1SRD5A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | ALKAHEST, INC. | 2024-01-25 | — | — | US | disclosed |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | ALKAHEST, INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4245295-A2 | COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR USE IN TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | Alkahest, Inc. (US) | 2023-09-20 | — | — | EP | disclosed |
| US-RE45323-E1 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2015-01-06 | — | — | US | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| EP-2114869-B1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2014-07-23 | — | — | EP | disclosed |
| US-8653075-B2 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-02-18 | — | — | US | disclosed |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-01-24 | — | — | US | disclosed |
| US-8278302-B2 | Substituted piperidines as CCR3 antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-10-02 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-8093266-B2 | Rho kinase inhibitors | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-10 | — | — | US | disclosed |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| US-20100041645-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-02-18 | — | — | US | disclosed |
| EP-2114869-A1 | RHO KINASE INHIBITORS | Boehringer Ingelheim International GmbH (DE) | 2009-11-11 | — | — | EP | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
| WO-2008086047-A1 | RHO KINASE INHIBITORS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-07-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041645-A1 | RHO KINASE INHIBITORS | CIT, ROCK1, RHOT2 | MAOA 829/4885MAOB 723/4885SLC6A4 3974/4885 |
| US-20230346764-A1 | Methods and Compositions for Treating Pruritus, Xerosis, and Associated Disease Using CCR3-Inhibitors | CCR3, CCR1, CCR4 | MAOA 4339/4885MAOB 3867/4885SLC6A4 3574/4885 |
| US-20240024305-A1 | METHODS AND COMPOSITIONS FOR TREATING RETINA-ASSOCIATED DISEASE USING CCR3-INHIBITORS | CCR3, CCR1, CCR4 | MAOA 4713/4885MAOB 4254/4885SLC6A4 4673/4885 |
| US-20100261687-A1 | SUBSTITUTED PIPERIDINES AS CCR3 ANTAGONISTS | CCR3, CCR1, CCR4 | MAOA 4694/4885MAOB 4531/4885SLC6A4 992/4885 |
| US-20130023517-A1 | Therapeutic methods employing substituted piperidines which are CCR3 antagonists | CCR3, CCR1, CCR4 | MAOA 4706/4885MAOB 4353/4885SLC6A4 963/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.